KATHRYN LEE-YOUNG: Open Payments
NPI 1629495155 · WESTMINSTER, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,367 in 58 payments from 16 companies in 2025. Trend: 2023 $694 · 2024 $1,298 · 2025 $1,367
Food & beverage: $1,367
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 12 | $264 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $243 |
| Ipsen Biopharmaceuticals, Inc | 8 | $202 |
| ABBVIE INC. | 8 | $147 |
| Gilead Sciences, Inc. | 4 | $103 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $75 |
| ORPHALAN INC | 3 | $71 |
| GENZYME CORPORATION | 2 | $56 |
| Amgen Inc. | 2 | $38 |
| Celltrion USA Inc. | 2 | $32 |
Products named: REZDIFFRA, ENTYVIO, IQIRVO, XIFAXAN, CREON, CUVRIOR, LINZESS, DUPIXENT.
Industry payments across MD — which companies pay providers there.
